Alcobra Ltd. (NASDAQ:ADHD) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research report issued on Wednesday. The brokerage presently has a $1.25 price objective on the biotechnology company’s stock. Zacks Investment Research‘s price target would indicate a potential upside of 26.26% from the company’s current price.

According to Zacks, “Alcobra Ltd. is a biopharmaceutical company. It focuses on the development and commercialization of drugs to treat attention deficit hyperactivity disorder. Alcobra Ltd. is headquartered in Tel Aviv, Israel. “

Several other research firms have also recently weighed in on ADHD. Jefferies Group LLC reiterated a “hold” rating and set a $1.25 price objective on shares of Alcobra in a research report on Monday, June 12th. Roth Capital cut shares of Alcobra from a “buy” rating to a “neutral” rating and decreased their price objective for the stock from $4.00 to $1.00 in a research report on Friday, September 29th. Two equities research analysts have rated the stock with a sell rating, seven have assigned a hold rating and one has given a buy rating to the company. Alcobra currently has a consensus rating of “Hold” and a consensus target price of $1.55.

Shares of Alcobra (ADHD) traded down 2.12% during trading on Wednesday, hitting $0.99. 320,389 shares of the stock traded hands. Alcobra has a 1-year low of $0.83 and a 1-year high of $2.75. The firm’s market capitalization is $27.29 million. The firm has a 50-day moving average of $1.05 and a 200-day moving average of $1.11.

Alcobra (NASDAQ:ADHD) last posted its quarterly earnings data on Friday, August 11th. The biotechnology company reported ($0.13) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.15) by $0.02. On average, equities analysts forecast that Alcobra will post ($0.50) earnings per share for the current year.

COPYRIGHT VIOLATION WARNING: “Alcobra Ltd. (ADHD) Stock Rating Upgraded by Zacks Investment Research” was published by American Banking News and is owned by of American Banking News. If you are accessing this piece on another domain, it was stolen and republished in violation of US & international copyright & trademark laws. The original version of this piece can be read at

A number of large investors have recently bought and sold shares of ADHD. Citadel Advisors LLC grew its holdings in Alcobra by 7,251.0% in the first quarter. Citadel Advisors LLC now owns 100,114 shares of the biotechnology company’s stock worth $114,000 after purchasing an additional 101,514 shares during the period. Royce & Associates LP grew its holdings in Alcobra by 15.5% in the first quarter. Royce & Associates LP now owns 745,055 shares of the biotechnology company’s stock worth $849,000 after purchasing an additional 100,000 shares during the period. Finally, Worth Venture Partners LLC grew its holdings in Alcobra by 35.6% in the second quarter. Worth Venture Partners LLC now owns 271,982 shares of the biotechnology company’s stock worth $305,000 after purchasing an additional 71,465 shares during the period. Institutional investors and hedge funds own 29.68% of the company’s stock.

About Alcobra

Alcobra Ltd is a development-stage biopharmaceutical company. The Company is focused on development and commercialization of its lead product candidates, including MDX and ADAIR. MDX is a oral drug, for the treatment of ADHD and other cognitive disorders, including Fragile X. MDX is a combined rapid onset ER formulation of the chemical pyridoxine pyroglutamate, which is more commonly known as metadoxine.

Get a free copy of the Zacks research report on Alcobra (ADHD)

For more information about research offerings from Zacks Investment Research, visit

Analyst Recommendations for Alcobra (NASDAQ:ADHD)

Receive News & Ratings for Alcobra Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alcobra Ltd. and related companies with's FREE daily email newsletter.